24 research outputs found

    Large eddy simulation of subsurface phytoplankton dynamics: an optimum condition for chlorophyll patchiness induced by Langmuir circulations

    Get PDF
    Phytoplankton patchiness occurs on a plethora of spatial and temporal scales which can be extremely patchy in both horizontal and vertical directions. This patchiness directly affects the dynamics of the overall bloom, so understanding the mechanisms for patchiness to occur on each scale is therefore integral to the understanding of plankton bloom dynamics as a whole. This modelling study aims to introduce a mechanism for patch formations which has had very little exposure, but is ubiquitous to the oceanic mixed layer – patchiness induced by the interaction between the nutrient upwelling and Langmuir circulations. By combining a Large-Eddy Simulation which resolves Langmuir circulations, with a Nutrient-Phytoplankton-Zooplankton biological model, one can examine the horizontal and vertical patchiness which results from a flux of nutrients into the bottom of the mixed layer. Here, phytoplankton form significant horizontal patchiness in a depth interval where vertical currents from Langmuir cells are apparent and turbulent mixing is not; this comprises the lower region of the surface mixed layer. Aggregations have frequently been observed in lower regions of the surface mixed layer and have been attributed to the high nutrient flux associated with the pycnocline. This modelling study also shows patches occurring in this region and it is hypothesised that Langmuir cells are a catalyst for patchiness. The results clearly demonstrate that for certain levels of wind forcing, which are strong enough to introduce turbulent mixing only to the upper part of the mixed layer whilst inducing deeper Langmuir circulation, patchiness is greatly enhanced

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

    CCDC 282119: Experimental Crystal Structure Determination

    No full text
    An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.,Related Article: L.A.Clapp, C.J.Siddons, D.G.VanDerveer, J.H.Reibenspies, S.B.Jones, R.D.Hancock|2006|Dalton Trans.||2001|doi:10.1039/b512017

    CCDC 282118: Experimental Crystal Structure Determination

    No full text
    An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.,Related Article: L.A.Clapp, C.J.Siddons, D.G.VanDerveer, J.H.Reibenspies, S.B.Jones, R.D.Hancock|2006|Dalton Trans.||2001|doi:10.1039/b512017

    Thigh-length compression stockings and DVT after stroke

    Get PDF
    Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease
    corecore